Evidence map›Paper›PMID 33335198›Full record

ArticleScientific reports2020

Population pharmacokinetic analysis of doripenem for Japanese patients in intensive care unit.

Ko Nonoshita, Yosuke Suzuki, Ryota Tanaka, Tetsuya Kaneko, Yoshifumi Ohchi, Yuhki Sato, Norihisa Yasuda, Koji Goto, Takaaki Kitano, Hiroki Itoh

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 10 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Ko NonoshitaDepartment of Clinical Pharmacy, Oita University Hospital, Hasama-machi, Oita, Japan. k-nonoshita@oita-u.ac.jp.
Yosuke SuzukiDepartment of Clinical Pharmacy, Oita University Hospital, Hasama-machi, Oita, Japan.
Ryota TanakaDepartment of Clinical Pharmacy, Oita University Hospital, Hasama-machi, Oita, Japan.
Tetsuya KanekoDepartment of Clinical Pharmacy, Oita University Hospital, Hasama-machi, Oita, Japan.
Yoshifumi OhchiDepartment of Anesthesiology and Intensive Care, Faculty of Medicine, Oita University, Hasama-machi, Oita, Japan.
Yuhki SatoDepartment of Clinical Pharmacy, Oita University Hospital, Hasama-machi, Oita, Japan.
Norihisa YasudaDepartment of Anesthesiology and Intensive Care, Faculty of Medicine, Oita University, Hasama-machi, Oita, Japan.
Koji GotoDepartment of Anesthesiology and Intensive Care, Faculty of Medicine, Oita University, Hasama-machi, Oita, Japan.
Takaaki KitanoDepartment of Anesthesiology and Intensive Care, Faculty of Medicine, Oita University, Hasama-machi, Oita, Japan.
Hiroki ItohDepartment of Clinical Pharmacy, Oita University Hospital, Hasama-machi, Oita, Japan.
Oita University Hospital · JPOita University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We aimed to construct a novel population pharmacokinetics (PPK) model of doripenem (DRPM) for Japanese patients in intensive care unit, incorporating the clearance of DRPM by continuous renal replacement therapy (CRRT). Twenty-one patients treated with DRPM (0.25 or 0.5 g) by intravenous infusion over 1 h were included in the study. Nine of the 21 patients were receiving CRRT. Plasma samples were obtained before and 1, 2, 4, 6 and 8 h after the first DRPM administration. PPK analysis was conducted by nonlinear mixed effects modeling using a two-compartment model. Total clearance (CL

Indexed as

Critical CareIntensive Care UnitsAnti-Bacterial AgentsDoripenemFemaleHumansJapanMaleModels, TheoreticalPublic Health SurveillanceAnti-Bacterial AgentsDoripenem

Identifiers

PMID33335198
PMCPMC7747597
OpenAlexW3113331683

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.